Results 1 to 10 of about 188,791 (289)

Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021

Lupus Science and Medicine
Background Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited.
Esi M Morgan, Jonathan D Cogen, Jordan E Roberts, Anna V Faino, Mersine A Bryan   +4 more
doaj   +1 more source

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis

Cancer Medicine, 2020
Background The aim of the study was to evaluate the cost‐effectiveness of lenalidomide plus rituximab vs rituximab alone in patients with relapsed or refractory indolent lymphoma.
Peng‐Fei Zhang, Dan Xie, Feng Wen, Qiu Li   +3 more
doaj   +1 more source

Hypokalemia after rituximab administration in nephrotic syndrome: two case reports

BMC Nephrology, 2023
Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse ...
Yiyun Song, Lin Ding, Xin An, Yi Zhao, Xianhua Li, Xiangdong Yang, Xiaoyan Xiao   +6 more
doaj   +1 more source

Kinetics of Rituximab Excretion into Urine and Peritoneal Fluid in Two Patients with Nephrotic Syndrome

Case Reports in Nephrology, 2017
Clinical observations suggest that treatment of Rituximab might be less effective in patients with nephrotic range proteinuria when compared to nonnephrotic patients.
Klaus Stahl, Michelle Duong, Anke Schwarz, A. D. Wagner, Hermann Haller, Mario Schiffer, Roland Jacobs   +6 more
doaj   +1 more source

Review of the role of rituximab in the management of adult minimal change disease and immune-mediated focal and segmental glomerulosclerosis

Glomerular Diseases, 2023
Background: Minimal change disease and primary FSGS are podocytopathies but are also immune-mediated diseases. Rituximab acts via multiple mechanisms by tilting the balance between autoreactive B & T cells in favor of regulatory B & T cells.
Ahsan Aslam, Abbal Koirala
doaj   +1 more source

Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases

Turkish Journal of Hematology, 2017
Objective: This paper prospectively evaluates the long-term followup [mean +- standard deviation (SD) duration: 89.7+-19.4 months] data of 15 patients (13 females and 2 males) with refractory symptomatic immune thrombocytopenia (ITP) treated with ...
Fehmi Hindilerden, Ipek Yönal Hindilerden, Mustafa Nuri Yenerel, Meliha Nalçacı, Reyhan Diz Küçükkaya   +4 more
doaj   +1 more source

Risk Factors for Persistent Hypogammaglobulinemia in Pediatric and Young Adult Patients Receiving Rituximab

Journal of Human Immunity
RationaleRituximab is an anti-CD20 monoclonal antibody that can cause persistent hypogammaglobulinemia (PH) in 20–45% of patients, depending on the patient population. Risk factors for PH in pediatric patients following rituximab have been inconsistently
Kevin Ackerman, Nathaniel Srikureja, Jennifer Heimall, Di Sun   +3 more
doaj   +1 more source

Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation

Scientific Reports, 2018
Sensitized patients received desensitization therapy with rituximab for kidney transplantation. However, the impact of rituximab dose on hepatitis B virus (HBV) reactivation is unknown.
Juhan Lee, Jun Yong Park, Deok Gie Kim, Jee Youn Lee, Beom Seok Kim, Myoung Soo Kim, Soon Il Kim, Yu Seun Kim, Kyu Ha Huh   +8 more
doaj   +1 more source

Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis

ACR Open Rheumatology, 2020
Objective Originator intravenous rituximab is an important rheumatology treatment but is costly, and administration requires several hours. Because biosimilar rituximab may cost less and subcutaneous rituximab requires a shorter visit, both may reduce ...
Zachary S. Wallace, Tyler Harkness, Kimberly G. Blumenthal, Hyon K. Choi, John H. Stone, Rochelle P. Walensky   +5 more
doaj   +1 more source

Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab

BMC Nephrology, 2020
Background Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving perioperative treatment with rituximab, which is associated with ...
Young Hoon Kim, Jee Yeon Kim, Dong Hyun Kim, Youngmin Ko, Ji Yoon Choi, Sung Shin, Joo Hee Jung, Su-Kil Park, Sung-Han Kim, Hyunwook Kwon, Duck Jong Han   +10 more
doaj   +1 more source